SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Novo Nordisk's logo on the facade of its building in Germany
Obesity
Novo Unveils Oral Wegovy in the US, With Out-of-Pocket Prices at $149 Per Month
After getting the crucial first-mover advantage with an FDA approval for a weight loss pill, Novo Nordisk looks to win the market before rival Lilly can arrive with its own oral option for obesity.
January 5, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
Oct 9, 2019 Milpitas / CA / USA - Johnson & Johnson Vision offices in Silicon Valley; Johnson & Johnson Vision Care, Inc. is part of the American multinational corporation Johnson&Johnson
Immunology and inflammation
J&J Stops Mid-stage Eczema Trial as $1.25B Asset Misses Efficacy Mark
J&J paid Numab Therapeutics $1.25 billion upfront for the asset in 2024 based on the belief that its dual mechanism of action could improve on existing therapies.
January 5, 2026
 · 
2 min read
 · 
Nick Paul Taylor
AbbVie's office in South San Francisco, California
Lung cancer
AbbVie Challenges Amgen With $100M Upfront for Trispecific Lung Cancer Drug
The Illinois-based pharma has committed more than $1 billion in milestones to secure rights to ZG006 and join a who’s who of drugmakers targeting the DLL3 protein.
January 5, 2026
 · 
2 min read
 · 
Nick Paul Taylor
A female doctor of mixed race, meets with a senior couple as she reviews recent test results with them. The senior couple of African decent, listens closely as they receive the good news.
IN PARTNERSHIP WITH TAKEDA
Takeda’s Commitment to Trial Representation is Shaping the Future of Clinical Research
One way Takeda lives out its values is by striving to ensure that patients are aware of and can access the company’s clinical trials. Two employees from its research and development organization discuss why representation matters and the work their team is doing to benefit patients now and in the future.
January 5, 2026
 · 
5 min read
 · 
BioSpace Insights
Doubtful person, hands on hips, choosing the way as multiple arrows on the road showing a mess of different directions. Choosing the correct pathway, difficult decision concept, confusion symbol.
FDA
Calls for Leadership Stability and Rare Disease Follow-Through at FDA in 2026
After a tumultuous year, experts call for stability while anticipating the first fruits of policies intended to expedite approvals for rare disease drugs.
January 5, 2026
 · 
9 min read
 · 
Tristan Manalac
Ace Spade Playing Card. Player or Magician Flick and Levitating Poker Card by Hand. Front View. Closeup and Dark Tone
Clinical research
5 Clinical Readouts to Watch in H1 2026
As 2026 begins, a slate of high-stakes clinical readouts—from a pivotal study of Novartis’ cardiovascular candidate pelacarsen to a Phase III test of Eli Lilly’s next-gen Alzheimer’s drug—are poised to reshape therapeutic landscapes.
January 5, 2026
 · 
7 min read
 · 
Ben Hargreaves
Bilogical genetic engineering research at laboratory, vector illustration. Doctor conduct experiment with mouse, study dna genes. Scientist near large animal and screen with work analysis.
Opinion
Addressing the Regulatory Reality of Replacing In Vivo Models in Drug Development
The FDA’s announcement that it will phase out in vivo testing requirements for monoclonal antibodies marks a seismic shift. Here’s how industry can adapt.
January 5, 2026
 · 
6 min read
 · 
Xiaoxia Li
Team building concept. Halftone clasped in a lock. Connection, business collaboration, teamwork. Contemporary collage. Group support. Startup launch. Doodle rocket, arrow. Community power
Mergers & acquisitions
Big Pharma Dealmakers Joined by Spunky Group of Biotech Buyers in Q4
While Novartis secured the biggest deal of the fourth quarter, a handful of riveting tales emerged from the bottom of the M&A list, including a zombie buyout and a bidding war. And no, we’re not talking about Metsera.
January 2, 2026
 · 
2 min read
 · 
Annalee Armstrong
Red engraving brain illustration in top view isolated on blue background
Depression
Biohaven Notches Another Psychiatric Failure Months After Key FDA Rejection
The major depressive disorder failure for BHV-7000 is the drug’s second, after Biohaven’s spinocerebellar ataxia treatment troriluzole was rejected by the FDA in November 2025.
January 2, 2026
 · 
1 min read
 · 
Annalee Armstrong
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS